Click Here for 5% Off Your First Aladdin Purchase!

GSK PERK inhibitor - ≥98%, high purity , CAS No.1337531-89-1, Inhibitor of eukaryotic translation initiation factor 2 alpha kinase 3;Inhibitor of myosin light chain kinase 2

  • Moligand™
  • ≥98%
Item Number
G355474
Grouped product items
SKUSizeAvailabilityPrice Qty
G355474-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$49.90
G355474-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$139.90
G355474-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$219.90
G355474-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$419.90
G355474-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$629.90
G355474-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$879.90

Basic Description

SynonymsGSK PERK Inhibitor|1337531-89-1|PERK-IN-4|CHEMBL2171125|1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-[3-fluoro-5-(trifluoromethyl)phenyl]ethanone|3-Fluoro-GSK2606414|1-(5-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2
Specifications & PurityMoligand™, ≥98%
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of eukaryotic translation initiation factor 2 alpha kinase 3;Inhibitor of myosin light chain kinase 2
Product Description

PERK-IN-4 is a potent and selective PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase) inhibitor with an IC 50 of 0.3 nM. PERK is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states.

Associated Targets

EIF2AK3 Tchem Eukaryotic translation initiation factor 2-alpha kinase 3 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NEK9 Tchem Serine/threonine-protein kinase Nek9 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NEK10 Tchem Serine/threonine-protein kinase Nek10 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NEK11 Tchem Serine/threonine-protein kinase Nek11 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NEK2 Tchem Serine/threonine-protein kinase Nek2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NEK3 Tchem Serine/threonine-protein kinase Nek3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NEK4 Tchem Serine/threonine-protein kinase Nek4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NEK7 Tchem Serine/threonine-protein kinase Nek7 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NEK1 Tchem Serine/threonine-protein kinase Nek1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NEK5 Tchem Serine/threonine-protein kinase Nek5 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NEK6 Tchem Serine/threonine-protein kinase Nek6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MYLK2 Tchem Myosin light chain kinase 2, skeletal/cardiac muscle 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-[3-fluoro-5-(trifluoromethyl)phenyl]ethanone
INCHI InChI=1S/C24H19F4N5O/c1-32-11-18(21-22(29)30-12-31-23(21)32)14-2-3-19-15(9-14)4-5-33(19)20(34)8-13-6-16(24(26,27)28)10-17(25)7-13/h2-3,6-7,9-12H,4-5,8H2,1H3,(H2,29,30,31)
InChi Key PXVQGBJMIQCDEX-UHFFFAOYSA-N
Canonical SMILES CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC(=C5)F)C(F)(F)F
Isomeric SMILES CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC(=C5)F)C(F)(F)F
PubChem CID 66561167
Molecular Weight 469.43

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Chemical and Physical Properties

Melt Point(°C)237-240° C (dec.)

Related Documents

References

1. Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW, Li WH, Heerding DA, Minthorn E, Mencken T et al..  (2012)  Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK)..  J Med Chem,  55  (16): (7193-207).  [PMID:22827572]
2. Moreno JA, Halliday M, Molloy C, Radford H, Verity N, Axten JM, Ortori CA, Willis AE, Fischer PM, Barrett DA et al..  (2013)  Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice..  Sci Transl Med,  (206): (206ra138).  [PMID:24107777]
3. Smith HL, Mallucci GR.  (2016)  The unfolded protein response: mechanisms and therapy of neurodegeneration..  Brain,  139  (Pt 8): (2113-21).  [PMID:27190028]
4. Axten JM, Romeril SP, Shu A, Ralph J, Medina JR, Feng Y, Li WH, Grant SW, Heerding DA, Minthorn E et al..  (2013)  Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development..  ACS Med Chem Lett,  (10): (964-8).  [PMID:24900593]

Solution Calculators